Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Bio-Plex Pro Human Cytokine Screening Panel

Bio-Rad Laboratories has launched the Bio-Plex Pro Human Cytokine Screening Panel, a multiplex assay that can identify and quantify 48 different analytes linked to heart disease, autoimmunity and allergy, cancer, and other conditions.

The panel detects targets related to adaptive immunity cytokines, pro-inflammatory cytokines, and anti-inflammatory cytokines, all in a single well. It is available in a 96-well kit format that includes premixed magnetic capture beads and detection antibodies, multiplexed standards and controls, secondary antibodies for fluorescence detection, and buffers. The panel is compatible with the Bio-Plex MAGPIX Multiplex Reader, Bio-Plex 200 and Bio-Plex 3D Multiplex Immunoassay Systems, LX200 Instrument, and Flexmap 3D System, and data can be managed and analyzed using Bio-Plex Manager and Bio-Plex Data Pro Software.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.